Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Biphasic Insulin Aspart 30 vs Insulin Glargine in T2D
NCT00469092Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- May 2007
- Primary completion
- Apr 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
Phase 4, randomised, open-label trial of Insulin aspart + insulin aspart protamine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Glycosylated Haemoglobin A1c at 26 weeks. Started May 2007; status: completed.
02
Drugs
Insulin aspart + insulin aspart protamine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00469092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00469092.